Clinical Trial Update: Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating combination chemotherapy plus either interferon alfa or rituximab for Stage III/IV lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Interferon Alfa (interferon alfa)
• Rituximab (rituximab)

Snippet

Sponsor: Hoag Memorial Hospital Presbyterian | Conditions: Lymphoma | Phase 2 | Status: WITHDRAWN